Compare JUBILANT LIFE SCIENCES with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES DR. REDDYS LAB JUBILANT LIFE SCIENCES/
DR. REDDYS LAB
 
P/E (TTM) x 13.3 16.9 79.0% View Chart
P/BV x 1.7 3.2 51.6% View Chart
Dividend Yield % 0.9 0.7 122.3%  

Financials

 JUBILANT LIFE SCIENCES   DR. REDDYS LAB
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
DR. REDDYS LAB
Mar-19
JUBILANT LIFE SCIENCES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs8982,875 31.2%   
Low Rs6181,888 32.7%   
Sales per share (Unadj.) Rs572.0930.2 61.5%  
Earnings per share (Unadj.) Rs36.2117.4 30.9%  
Cash flow per share (Unadj.) Rs59.5185.8 32.0%  
Dividends per share (Unadj.) Rs4.5020.00 22.5%  
Dividend yield (eoy) %0.60.8 70.7%  
Book value per share (Unadj.) Rs301.9844.4 35.8%  
Shares outstanding (eoy) m159.28166.07 95.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.6 51.7%   
Avg P/E ratio x20.920.3 103.1%  
P/CF ratio (eoy) x12.712.8 99.3%  
Price / Book Value ratio x2.52.8 89.0%  
Dividend payout %12.417.0 72.9%   
Avg Mkt Cap Rs m120,694395,496 30.5%   
No. of employees `0002.422.0 10.9%   
Total wages/salary Rs m19,26033,562 57.4%   
Avg. sales/employee Rs Th38,120.67,032.8 542.0%   
Avg. wages/employee Rs Th8,058.41,527.9 527.4%   
Avg. net profit/employee Rs Th2,414.3887.7 272.0%   
INCOME DATA
Net Sales Rs m91,108154,482 59.0%  
Other income Rs m3573,375 10.6%   
Total revenues Rs m91,466157,857 57.9%   
Gross profit Rs m17,39031,782 54.7%  
Depreciation Rs m3,70911,348 32.7%   
Interest Rs m2,198889 247.3%   
Profit before tax Rs m11,84022,920 51.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,2683,858 84.7%   
Profit after tax Rs m5,77019,500 29.6%  
Gross profit margin %19.120.6 92.8%  
Effective tax rate %27.616.8 164.0%   
Net profit margin %6.312.6 50.2%  
BALANCE SHEET DATA
Current assets Rs m45,848111,101 41.3%   
Current liabilities Rs m20,89758,973 35.4%   
Net working cap to sales %27.433.7 81.2%  
Current ratio x2.21.9 116.5%  
Inventory Days Days5779 71.6%  
Debtors Days Days5194 54.1%  
Net fixed assets Rs m65,498101,245 64.7%   
Share capital Rs m159830 19.2%   
"Free" reserves Rs m47,930139,406 34.4%   
Net worth Rs m48,089140,236 34.3%   
Long term debt Rs m42,42922,000 192.9%   
Total assets Rs m114,685224,656 51.0%  
Interest coverage x6.426.8 23.8%   
Debt to equity ratio x0.90.2 562.4%  
Sales to assets ratio x0.80.7 115.5%   
Return on assets %6.99.1 76.6%  
Return on equity %12.013.9 86.3%  
Return on capital %12.414.9 83.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,42288,673 14.0%   
Fx outflow Rs m17,22719,104 90.2%   
Net fx Rs m-4,80569,569 -6.9%   
CASH FLOW
From Operations Rs m11,21528,704 39.1%  
From Investments Rs m-10,118-7,727 130.9%  
From Financial Activity Rs m6,574-21,326 -30.8%  
Net Cashflow Rs m7,612-314 -2,424.3%  

Share Holding

Indian Promoters % 45.6 25.5 178.8%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 5.4 161.1%  
FIIs % 21.2 35.3 60.1%  
ADR/GDR % 0.0 18.5 -  
Free float % 21.1 15.3 137.9%  
Shareholders   23,815 75,885 31.4%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Higher; IT and Banking Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended higher. Benchmark Indices were highly volatile swinging between positive and negative territory.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Nov 14, 2019 03:37 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - ELDER PHARMA COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS